Open AccessSystematic review and meta-analysis of the epidemiology of Lassa virus in humans, rodents and other mammals in sub-Saharan Africa
Author(s) -
Sébastien Kenmoe,
Serges Tchatchouang,
Jean Thierry EbogoBelobo,
Aude Christelle Ka’e,
Gadji Mahamat,
Raïssa Estelle Guiamdjo Simo,
Arnol BowoNgandji,
Cynthia Paola Demeni Emoh,
Emmanuel Che,
Dimitri Tchami Ngongang,
Marie AmougouAtsama,
Nathalie Diane Nzukui,
Chris André Mbongue Mikangue,
Donatien Serge Mbaga,
Sorel Kenfack,
Sandrine Rachel Kingue Bebey,
Nathalie Amvongo-Adjia,
Atembeh Noura Efietngab,
Hervé Raoul Tazokong,
Abdou Fatawou Modiyinji,
Cyprien Kengne-Ndé,
Serge Alain Sadeuh-Mba,
Richard Njouom
Publication year - 2020
Publication title -
plos neglected tropical diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.99
H-Index - 135
eISSN - 1935-2735
pISSN - 1935-2727
DOI - 10.1371/journal.pntd.0008589
Subject(s) - lassa virus , virology , epidemiology , lassa fever , biology , meta analysis , virus , medicine , pathology
Accurate data on the Lassa virus (LASV) human case fatality rate (CFR) and the prevalence of LASV in humans, rodents and other mammals are needed for better planning of actions that will ultimately reduce the burden of LASV infection in sub-Saharan Africa. In this systematic review with meta-analysis, we searched PubMed, Scopus, Africa Journal Online, and African Index Medicus from 1969 to 2020 to obtain studies that reported enough data to calculate LASV infection CFR or prevalence. Study selection, data extraction, and risk of bias assessment were conducted independently. We extracted all measures of current, recent, and past infections with LASV. Prevalence and CFR estimates were pooled using a random-effect meta-analysis. Factors associated with CFR, prevalence, and sources of between-study heterogeneity were determined using subgroup and metaregression analyses. This review was registered with PROSPERO, CRD42020166465. We initially identified 1,399 records and finally retained 109 reports that contributed to 291 prevalence records from 25 countries. The overall CFR was 29.7% (22.3–37.5) in humans. Pooled prevalence of LASV infection was 8.7% (95% confidence interval: 6.8–10.8) in humans, 3.2% (1.9–4.6) in rodents, and 0.7% (0.0–2.3) in other mammals. Subgroup and metaregression analyses revealed a substantial statistical heterogeneity explained by higher prevalence in tissue organs, in case-control, in hospital outbreak, and surveys, in retrospective studies, in urban and hospital setting, in hospitalized patients, and in West African countries. This study suggests that LASV infections is an important cause of death in humans and that LASV are common in humans, rodents and other mammals in sub-Saharan Africa. These estimates highlight disparities between sub-regions, and population risk profiles. Western Africa, and specific key populations were identified as having higher LASV CFR and prevalence, hence, deserving more attention for cost-effective preventive interventions.